360Dx: Quotient Launching Multimodal, Multiplex Microarray for Transfusion Diagnostics

NEW YORK ─ Microarray test developer Quotient has entered the market for transfusion diagnostic testing with a multiplex, multimodal platform and is eyeing the development of the system for additional diagnostic applications. Though sales of the firm’s manually applied Alba by Quotient reagents currently account for almost all of the Eysins, Switzerland-based company’s revenues, Quotient believes its automated microarray platform, MosaiQ, will become a mainstay of its future revenue growth, said Manuel Mendez, who took over as the company’s new CEO at the beginning of April.

To read the full article, visit: 360Dx.com

Trending Topics

Our passion for the work we do is matched only by our commitment to consistently provide the best customer experience possible.

November 20, 2023

Unveiling The L.I.V.E Xchange showroom and innovation space

We are delighted to unveil The L.I.V.E. Xchange, our new showroom and innovation space, at our headquarters in Eysins, Switzerland. The L.I.V.E. Xchange was created to give our customers, development partners, distributors, and other stakeholders access to a dynamic environment
November 16, 2023

AliveDx and Rowad Medical Services sign distribution agreement in the Kingdom of Saudi Arabia

AliveDx and Rowad Medical Services have signed a distribution agreement, which will enable Rowad Medical Services to distribute AliveDx’s products, Alba and MosaiQ®, in the Kingdom of Saudi Arabia. The distribution agreement takes effect immediately. This strategic partnership reaffirms AliveDx’s
November 14, 2023

AliveDx held its first Golden Partners Meeting

Last week, AliveDx held its first Golden Partners Meeting at its headquarters in Eysins, Switzerland. For four consecutive days, our Golden Partners from all around the world engaged with our management team and representatives from our commercial, regulatory, and technical
November 13, 2023

MosaiQ® Abstract Presented at Annual ACR Convergence Meeting

We are excited to announce that our abstract on the microarray prototype for the serological detection of eleven IgG autoantibodies commonly found in Connective Tissue Diseases was presented at ACR Convergence 2023, held in San Diego, California. Our poster titled
October 24, 2023

AliveDx receives three IVDR CE marks for its Multiplexed Autoimmune Diagnostics Solution

AliveDx receives three IVDR CE Marks for its automated, multiplexed MosaiQ® solution, enabling faster diagnosis of Connective Tissue Diseases (CTD). Eysins, 24 October 2023 — AliveDx is proud to announce it has received three CE Marks for: Its MosaiQ Centromere
September 28, 2023

Unveiling an Exciting Rebranding Initiative: AliveDx

We are thrilled to announce a transformative milestone in our journey—a comprehensive rebranding effort aimed at better reflecting the company’s mission, values, and vision for the future.